GLP-1 Side Effects by Week: What’s Normal, What’s Not

Side effects on a GLP-1 usually do not hit in one straight line. The common pattern is rougher when you start, rougher again after each dose increase, then quieter once the dose stays put. That matters because a lot of people assume something is “going wrong” when symptoms come back in week 5 or week 9. Often it is just the next step in titration.

The actual numbers make the pattern less mysterious. In pooled STEP 1 to 3 obesity trials, semaglutide 2.4 mg caused nausea in 43.9% of participants, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.2%, versus 16.1%, 15.9%, 6.3%, and 11.1% on placebo. Most events were non-serious, mild to moderate, temporary, and most common during or shortly after dose escalation. 3 The current Wegovy label reports a similar picture in adults: nausea 44%, diarrhea 30%, vomiting 24%, constipation 24%, fatigue 11%, dyspepsia 9%, and gastroesophageal reflux disease 5%. 6

Tirzepatide follows the same broad arc. In the current Zepbound label, nausea affected 25%, 29%, and 28% of patients at 5 mg, 10 mg, and 15 mg; constipation 17%, 14%, and 11%; fatigue 5%, 6%, and 7%; dyspepsia 9%, 9%, and 10%; and reflux 4%, 4%, and 5%, versus 8%, 5%, 3%, 4%, and 2% on placebo. The label also states that most nausea, vomiting, and diarrhea events happened during dose escalation and decreased over time. 7

If you want the bigger picture first, start with our complete guide to GLP-1 receptor agonists. If one symptom is dominating, go deeper with how to manage GLP-1 nausea, GLP-1 fatigue timeline, and GLP-1 side effects: what to expect and how to manage them.

Why the Timeline Matters

GLP-1 receptor agonists slow gastric emptying, which means food leaves the stomach more slowly, and they change appetite signaling between the gut and brain. 5 That helps with fullness and weight loss, but it also explains why the same normal-sized meal can suddenly feel too heavy, why constipation can show up after you start eating less, and why reflux or indigestion can flare if you eat quickly or lie down too soon after dinner.

The key practical point is this: side effects usually track dose changes better than calendar time. That is why week 6 can feel worse than week 4. You are not necessarily “failing the medication.” You may just be feeling the next jump in exposure.

Week-by-Week: What Is Usually Normal

Weeks 1 to 4: Starting dose

This is the adjustment phase. Starting doses are intentionally low because the goal is to let your gut and appetite signals adapt before the stronger doses arrive. Even so, this is when many people first notice that they are full earlier, less interested in rich food, or mildly nauseated for a day or two after the injection. 6 7

What is common in this phase:

  • Mild nausea after meals or the day after the shot
  • Early fullness after much smaller portions
  • Constipation if your total food and fluid intake drop fast
  • Fatigue when the appetite drop leads to under-eating
  • Heartburn or dyspepsia after larger evening meals

What is usually reassuring:

  • Symptoms come and go instead of staying intense all week
  • Symptoms clearly tie to the injection day, meal size, or greasy food
  • You can still drink fluids and function normally

Weeks 5 to 8: First dose increase

This is where a lot of people get caught off guard. They think, “I was starting to feel fine, and now I feel bad again.” That is common. The first escalation often produces the clearest flare in nausea, fullness, reflux, and bathroom changes because the appetite effect is stronger and gastric emptying is slowed more than before. The semaglutide pooled tolerability analysis found that GI adverse events were most common during or shortly after dose escalation, not evenly spread across treatment. 3 The tirzepatide pooled SURMOUNT analysis reported the same general pattern. 4

What is common in this phase:

  • Nausea returning for a few days after the new dose
  • Constipation from lower intake, less fiber, and less total stool volume
  • Fatigue because eating “intuitively” now means eating very little
  • Reflux or indigestion if you still try to eat a pre-GLP-1 dinner size

What is still usually normal:

  • A flare after the dose increase that then eases again
  • Needing smaller meals and more fluids for a few days
  • Feeling better by the end of the week than right after the shot

Weeks 9 to 16: Mid-titration

This is often the most uneven part. By now, many patients are losing noticeable weight, but the cycle can become obvious: tougher after the shot, better later in the week, then temporarily worse again after the next increase. In the current Zepbound label, overall gastrointestinal adverse reactions occurred in 56% of patients across all three maintenance doses versus 30% on placebo, and the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. 7

This is also when constipation and fatigue can become more practical than dramatic. You may not be vomiting. You may just be eating less, drinking less, and wondering why energy is low and bowel movements are less frequent. In other words, the symptom driver may be the routine you have slipped into, not just the drug itself.

Maintenance dose weeks

Once the dose stays stable for a few weeks, many people stop having constant side effects. The more typical pattern becomes “I am mostly fine unless I overeat, eat very late, or move up too fast.” In pooled STEP analyses, gastrointestinal adverse events were generally transient and most prominent during escalation, not forever. 8

What is still common at maintenance:

  • Mild nausea after unusually large meals
  • Reflux when dinner is too heavy or too close to bedtime
  • Constipation if protein and fluids are prioritized but fiber is ignored
  • Fatigue when the calorie deficit has quietly become too aggressive

What is less reassuring:

  • Symptoms that are just as strong every day as they were in the first month
  • Repeated vomiting on a stable dose
  • Pain that feels severe rather than uncomfortable

Symptom-by-Symptom: What Usually Settles, What Usually Does Not

Nausea

Nausea is the most predictable GLP-1 side effect. In STEP 1, semaglutide 2.4 mg was associated with nausea in 44.2% of participants versus 17.4% on placebo. 1 In SURMOUNT-1, nausea occurred in 24% to 33% of tirzepatide-treated participants depending on dose, versus 9.5% on placebo. 2

Usually normal:

  • Worse after starting or after each dose increase
  • Better with smaller, lower-fat meals
  • Better later in the week than the day after the shot

Not normal to keep managing at home:

  • Repeated vomiting
  • Inability to keep fluids down
  • Nausea with severe abdominal pain

Constipation

Constipation often gets less attention than nausea, but it is common. In pooled STEP 1 to 3 data, constipation affected 24.2% of semaglutide-treated participants versus 11.1% on placebo. 3 In the current Zepbound label, constipation affected 17%, 14%, and 11% of patients at 5 mg, 10 mg, and 15 mg, versus 5% on placebo. 7

Usually normal:

  • Fewer bowel movements after intake drops
  • Harder stools when fluids are low
  • A flare after dose escalation

Not normal:

  • Severe abdominal swelling
  • No gas or stool with worsening pain
  • Vomiting with constipation, which can suggest obstruction rather than simple slowdown

Fatigue

Fatigue is real but usually indirect. The medication lowers appetite, people eat less, fluids drop, sleep gets worse from GI symptoms, and energy tanks. The Wegovy label lists fatigue in 11% of adults versus 5% on placebo. The Zepbound label reports fatigue in 5% to 7% depending on dose versus 3% on placebo. 6 7

Usually normal:

  • Tiredness that is strongest for 1 to 3 days after the shot
  • Fatigue that improves when protein and fluid intake improve
  • Lower workout capacity during dose-escalation weeks

Not normal:

  • Severe fatigue all week on a stable dose
  • Fatigue with fainting, shortness of breath, chest pain, or palpitations
  • Fatigue that does not fit the injection timing at all

Heartburn and dyspepsia

These are the “full, burning, food just sits there” symptoms. In the Wegovy label, dyspepsia occurred in 9% and reflux in 5% of adults, versus 3% and 3% on placebo. In the Zepbound label, dyspepsia occurred in 9% to 10% and reflux in 4% to 5%, versus 4% and 2% on placebo. 6 7

Usually normal:

  • Worse after large meals
  • Worse when eating late or lying down soon after eating
  • Better with smaller meals and slower eating

Not normal:

  • Black stools
  • Vomiting blood or coffee-ground material
  • Chest pain that is new, severe, or not clearly reflux-like

Red Flags Table: Call Soon vs Go Now

SituationWhat it often meansAction
Mild nausea, constipation, fullness, or reflux after a dose increaseCommon adjustment effectHome management is usually reasonable
Symptoms improve later in the weekTypical dose-timing patternKeep tracking before escalating again
Symptoms still disrupt work, hydration, or meals by the next injectionCurrent dose may be too muchContact your prescriber soon
Repeated vomiting or inability to keep fluids downRisk of dehydration or kidney injuryContact your prescriber the same day; urgent care if severe
Severe persistent abdominal pain, especially pain going to the backPancreatitis or gallbladder issue must be ruled outSeek urgent evaluation
Yellow skin or eyes, dark urine, severe right upper abdominal painPossible gallbladder or liver issueSeek urgent evaluation
No stool or gas with worsening abdominal pain and vomitingPossible obstruction, not routine constipationSeek urgent evaluation
Vomiting blood, black stools, fainting, or confusionGI bleeding or severe dehydrationEmergency care

The Practical Weekly Checklist

Use this before every injection:

  • Did last week’s symptoms settle before today?
  • Am I drinking enough to produce normal, light-colored urine?
  • Have I been eating smaller meals, or am I still testing my old portion sizes?
  • Has constipation become a pattern instead of a one-off?
  • If I am still struggling, have I asked whether I should hold this dose longer instead of escalating?

That last question matters. The labels and trial programs were built around gradual titration because side effects often get worse at each new dose before they get better again. 3 4

Bottom Line

The normal GLP-1 side-effect timeline is bumpy, not smooth. Symptoms commonly flare when you start and when you increase the dose, then improve once the dose stabilizes. That is true for semaglutide and tirzepatide, and the published trial data and FDA labels both point in the same direction.

The part to take seriously is not whether you feel perfect. It is whether the pattern still looks like routine adjustment. Mild nausea, constipation, fatigue, or reflux that improve later in the week are common. Severe pain, repeated vomiting, dehydration, jaundice, or GI bleeding are not.

If you want more practical GLP-1 explainers like this, join the email list for week-by-week symptom guides, food checklists, and dosing cheat sheets.